Mice immunized with the potassium thiocyanate extract of Pasteurella haemolytica, serotype 1, were found to resist a challenge infection of P. multocida type A, thus demonstrating cross-protection. This finding was further supported by the finding that an antiserum directed against the potassium thiocyanate extract of P. haemolytica was bactericidal to P. multocida and vice versa.
sular antigens of P. multocida type B and various other gram-negative species (including different serotypes of P. multocida) and one strain of P. haemolytica (isolated from a case of lamb septicemia), was reported by Prince and Smith (5, 6) . However, no information on cross-protection was provided.
Recently, this laboratory reported (T. K. S. Mukkur, submitted for publication) the extraction of glycoprotein antigen(s) from P. multocida type A (Heddleston serotype 8) by the use of an aqueous solution of potassium thiocyanate (KSCN) , which imparted 100% protection against an experimental challenge infection with a homologous strain of P. multocida. In this communication, I report data that demonstrate cross-protection between P. multocida type A (Heddleston serotype 8) and P. haemolytica, serotype 1. MATERIALS AND METHODS Source and type 'of P. multocida and P. haemolytica. P Table 1 . Animals immunized with 0.5 OD276 unit (Mukkur, submitted for publication) showed 60% protection, whereas those immunized with 1.0 OD unit survived a challenge infection with 22 mean lethal doses of P. multocida. On the other hand, one dose of Formalin-killed P. haemolytica vaccine protected only 20% of the immunized mice against a challenge infection with 22 mean lethal doses of viable, encapsulated P. multocida, and administration of two doses protected 70% of the immunized mice. All of the control mice, which were sham-immunized with saline, died upon challenge with either 2.2 or 22 mean lethal doses of P. multocida.
Bactericidal titers. Whereas the bactericidal titer of anti-P. hemolytica extract antiserum against P. haemolytica was found to be 160, that against P. multocida was 80. Similarly, anti-P. multocida extract antiserum exhibited a bactericidal titer of 160 against P. multocida and of 80 against P. haemolytica. The bactericidal tests carried out with anti-formalinized P. haemolytica (one dose) against P. multocida revealed a titer of 20, and that with anti-fornalinized P. haemolytica (two doses) was 40 ( Table  2) . Since antisera represented pooled preparations, individual variations could be not calculated.
The sera obtained from the beef calves immunized with P. multocida KSCN extract were also bactericidal to P. haemolytica (Table 2) . (5, 6) reported cross-reactivity between different strains of P. multocida as judged by Ouchterlony gel diffusion precipitin analysis. However, the approach adopted in my investigation consisted of immuniinng mice with either the KSCN extract or formalinized whole cells of P. haemolytica followed by a challenge with P. multocida to determine cross-protection. Instead of P. haemolytica, P. multocida was used for the challenge infection because it is not pathogenic for mice. It was exciting that mice immunized with 1.0 OD unit of P. haemolytica KSCN extract protected 100% of the immunized with formalinized P. haemolytica vaccine. The results ofthe challenge experiments were further supported by those of the bactericidal tests (Table 2), i.e., the development of bactericidal antibodies against P. multocida in animals immunized with either P. haemolytica KSCN extract or fornalinized P. haemolytica vaccines. Furthermore, bovine anti-KSCN extract antisera were also found to be bactericidal to P. haemolytica, serotype 1.
It is, therefore, amply clear that P. multocida type A and P. haemolytica possess a common immunogenic antigen(s). This is significant in view of the fact that both species are important in the etiology of shipping fever pneumonia of cattle (3) . Furthermore, the recent observation that the two antigenic components of KSCN extracts from various avain serotypes of P. multocida (1, 3 to 16) are antigenically identical (Mukkur, submitted for publication) adds another dimension to this finding of cross-protection. If similar observations are recorded for bovine serotypes of P. multocida, one cannot help being optimistic about the possibility of a vaccine being prepared from a single serotype of the microorganism, especially since crossreactivity between bovine and avian strains of P. multocida, has already been reported (6) . The comparative immunogenicity of the P. multocida and P. haemolytica extracts in cattle is currently being evaluated.
